FR2846667B1 - VARIABLE FRAGMENTS OF SINGLE-CHAIN CAMELIDE ANTIBODIES DIRECTED AGAINST BETA-AMYLOID PEPTIDE 1-42 AND THEIR APPLICATIONS FOR DIAGNOSIS AND TREATMENT OF NEUROAGREGATIVE DISEASES - Google Patents

VARIABLE FRAGMENTS OF SINGLE-CHAIN CAMELIDE ANTIBODIES DIRECTED AGAINST BETA-AMYLOID PEPTIDE 1-42 AND THEIR APPLICATIONS FOR DIAGNOSIS AND TREATMENT OF NEUROAGREGATIVE DISEASES

Info

Publication number: FR2846667B1
Authority: FR; France
Prior art keywords: neuroagregative; camelide; diagnosis; diseases; chain
Prior art date: 2002-11-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

FR0213866A

Other languages

French (fr)

Other versions

FR2846667A1 (en

Inventor

Francois Rougeon

Pierre Lafaye

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Centre National de la Recherche Scientifique CNRS

Institut Pasteur

Original Assignee

Centre National de la Recherche Scientifique CNRS

Institut Pasteur

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-11-06

Filing date

2002-11-06

Publication date

2004-12-31

2002-11-06 Application filed by Centre National de la Recherche Scientifique CNRS, Institut Pasteur filed Critical Centre National de la Recherche Scientifique CNRS

2002-11-06 Priority to FR0213866A priority Critical patent/FR2846667B1/en

2003-11-06 Priority to AU2003290158A priority patent/AU2003290158A1/en

2003-11-06 Priority to PCT/FR2003/003319 priority patent/WO2004044204A2/en

2004-05-07 Publication of FR2846667A1 publication Critical patent/FR2846667A1/en

2004-12-31 Application granted granted Critical

2004-12-31 Publication of FR2846667B1 publication Critical patent/FR2846667B1/en

2022-11-06 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 title 1
238000003745 diagnosis Methods 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
239000012634 fragment Substances 0.000 title 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Neurology (AREA)
General Health & Medical Sciences (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Toxicology (AREA)
Cell Biology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biotechnology (AREA)
Veterinary Medicine (AREA)
Psychiatry (AREA)
Microbiology (AREA)
Hospice & Palliative Care (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Peptides Or Proteins (AREA)

FR0213866A 2002-11-06 2002-11-06 VARIABLE FRAGMENTS OF SINGLE-CHAIN CAMELIDE ANTIBODIES DIRECTED AGAINST BETA-AMYLOID PEPTIDE 1-42 AND THEIR APPLICATIONS FOR DIAGNOSIS AND TREATMENT OF NEUROAGREGATIVE DISEASES Expired - Fee Related FR2846667B1 (en)

Priority Applications (3)

Application Number	Priority Date	Filing Date	Title
FR0213866A FR2846667B1 (en)	2002-11-06	2002-11-06	VARIABLE FRAGMENTS OF SINGLE-CHAIN CAMELIDE ANTIBODIES DIRECTED AGAINST BETA-AMYLOID PEPTIDE 1-42 AND THEIR APPLICATIONS FOR DIAGNOSIS AND TREATMENT OF NEUROAGREGATIVE DISEASES
AU2003290158A AU2003290158A1 (en)	2002-11-06	2003-11-06	Variable fragments of single-chain camelide antibodies and uses thereof for diagnosing and treating various pathologies
PCT/FR2003/003319 WO2004044204A2 (en)	2002-11-06	2003-11-06	Variable fragments of single-chain camelide antibodies and uses thereof for diagnosing and treating various pathologies

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0213866A FR2846667B1 (en)	2002-11-06	2002-11-06	VARIABLE FRAGMENTS OF SINGLE-CHAIN CAMELIDE ANTIBODIES DIRECTED AGAINST BETA-AMYLOID PEPTIDE 1-42 AND THEIR APPLICATIONS FOR DIAGNOSIS AND TREATMENT OF NEUROAGREGATIVE DISEASES

Publications (2)

Publication Number	Publication Date
FR2846667A1 FR2846667A1 (en)	2004-05-07
FR2846667B1 true FR2846667B1 (en)	2004-12-31

Family

ID=32104491

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR0213866A Expired - Fee Related FR2846667B1 (en)	2002-11-06	2002-11-06	VARIABLE FRAGMENTS OF SINGLE-CHAIN CAMELIDE ANTIBODIES DIRECTED AGAINST BETA-AMYLOID PEPTIDE 1-42 AND THEIR APPLICATIONS FOR DIAGNOSIS AND TREATMENT OF NEUROAGREGATIVE DISEASES

Country Status (3)

Country	Link
AU (1)	AU2003290158A1 (en)
FR (1)	FR2846667B1 (en)
WO (1)	WO2004044204A2 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6761888B1 (en)	2000-05-26	2004-07-13	Neuralab Limited	Passive immunization treatment of Alzheimer's disease
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en)	2000-05-26	2009-09-15	Elan Pharma International Limited	Treatment of amyloidogenic disease
US7700751B2 (en)	2000-12-06	2010-04-20	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (en)	2000-12-06	2002-07-02	Wyeth Corp	HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (en)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid β (1-42) oligomers, process for their preparation and their use
PE20050627A1 (en)	2003-05-30	2005-08-10	Wyeth Corp	HUMANIZED ANTIBODIES THAT RECOGNIZE THE BETA AMYLOID PEPTIDE
JPWO2005105998A1 (en) *	2004-04-27	2008-07-31	財団法人化学及血清療法研究所	Human anti-amyloid β peptide antibody and antibody fragment thereof
BRPI0518151A2 (en) *	2004-10-13	2009-06-16	Ablynx Nv	polypeptides against amyloid-beta, nucleic acid encoding such polypeptide, composition comprising such polypeptide, method for producing a polypeptide and use thereof
US7625560B2 (en)	2004-12-15	2009-12-01	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
PE20061329A1 (en)	2004-12-15	2006-12-08	Neuralab Ltd	HUMANIZED AB ANTIBODIES TO IMPROVE COGNITION
WO2006066118A2 (en) *	2004-12-15	2006-06-22	Neuralab Limited	Contextual fear test for predicting efficacy of alzheimer immunotherapeutic treatment
US20100323905A1 (en) *	2005-09-23	2010-12-23	Academisch Ziekenhuis Leiden	Vhh for the Diagnosis, Prevention and Treatment of Diseases Associated with Protein Aggregates
EP1785434A1 (en) *	2005-11-11	2007-05-16	Ludwig-Maximilians-Universität München	Targeting and tracing of antigens in living cells
KR101439828B1 (en)	2005-11-30	2014-09-17	애브비 인코포레이티드	Monoclonal antibodies against amyloid beta protein and uses thereof
JP5475994B2 (en)	2005-11-30	2014-04-16	アッヴィ・インコーポレイテッド	Anti-Aβ globulomer antibody, antigen-binding portion thereof, corresponding hybridoma, nucleic acid, vector, host cell, method for producing said antibody, composition comprising said antibody, use of said antibody and method of using said antibody.
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en)	2007-02-27	2008-09-04	Abbott Gmbh & Co. Kg	Method for the treatment of amyloidoses
EA200901140A1 (en)	2007-03-01	2010-04-30	Пробиодруг Аг	NEW USE OF GLUTAMINYL CYCLLASE INHIBITORS
EP1978035A1 (en) *	2007-04-05	2008-10-08	Hans-Knöll-Institut Leibniz-Institut für Naturstoff-Forschung	Anti-amyloid antibodies and their use in diagnosis and therapy of amyloid diseases
US8003097B2 (en)	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
JP5667440B2 (en)	2007-04-18	2015-02-12	プロビオドルグエージー	Thiourea derivatives as glutaminyl cyclase inhibitors
EP2009445A1 (en) *	2007-06-29	2008-12-31	Institut Pasteur	Use of a camelid single-domain antibody for detecting an oligomeric form of an amyloid beta peptide and its applications
EP2008666A1 (en)	2007-06-29	2008-12-31	Institut Pasteur	Use of VHH antibodies for the preparation of peptide vectors for delivering a substance of interest and their applications
SI2182983T1 (en)	2007-07-27	2014-09-30	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
JO3076B1 (en)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	Immunotherapy regimes dependent on apoe status
AU2009267417A1 (en) *	2008-07-07	2010-01-14	Athera Biotechnologies Ab	New therapeutic and diagnostic methods for Alzheimer's disease
EP2143735A1 (en)	2008-07-10	2010-01-13	Institut Pasteur	Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
US20100136584A1 (en) *	2008-09-22	2010-06-03	Icb International, Inc.	Methods for using antibodies and analogs thereof
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
CN102695546B (en)	2009-09-11	2014-09-10	前体生物药物股份公司	Heterocylcic derivatives as inhibitors of glutaminyl cyclase
CA2788275A1 (en)	2010-03-03	2011-09-09	Boehringer Ingelheim International Gmbh	Biparatopic abeta binding polypeptides
US9181233B2 (en)	2010-03-03	2015-11-10	Probiodrug Ag	Inhibitors of glutaminyl cyclase
US8269019B2 (en)	2010-03-10	2012-09-18	Probiodrug Ag	Inhibitors
ES2684475T3 (en)	2010-04-15	2018-10-03	Abbvie Inc.	Proteins that bind to beta amyloid
JP5945532B2 (en)	2010-04-21	2016-07-05	プロビオドルグエージー	Benzimidazole derivatives as inhibitors of glutaminyl cyclase
EP3533803B1 (en)	2010-08-14	2021-10-27	AbbVie Inc.	Anti-amyloid-beta antibodies
EP2621953B1 (en)	2010-09-30	2017-04-05	Ablynx N.V.	Biological materials related to c-met
US11644471B2 (en)	2010-09-30	2023-05-09	Ablynx N.V.	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
US8530670B2 (en)	2011-03-16	2013-09-10	Probiodrug Ag	Inhibitors
SG10201605048XA (en)	2011-06-23	2016-07-28	Ablynx Nv	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
SI2723771T1 (en)	2011-06-23	2019-12-31	Ablynx Nv	Serum albumin binding proteins
US10112987B2 (en)	2012-01-09	2018-10-30	Icb International, Inc.	Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
US10112988B2 (en)	2012-01-09	2018-10-30	Icb International, Inc.	Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
EP2873679A1 (en)	2013-11-13	2015-05-20	F.Hoffmann-La Roche Ag	Camelid single-domain antibody directed against amyloid bêta and methods for producing conjugates thereof
EP2873680A1 (en)	2013-11-13	2015-05-20	F.Hoffmann-La Roche Ag	Oligopeptide and methods for producing conjugates thereof
EP2899208A1 (en)	2014-01-28	2015-07-29	F.Hoffmann-La Roche Ag	Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
HUE056738T2 (en)	2014-05-16	2022-03-28	Ablynx Nv	Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
AU2015261536B2 (en)	2014-05-16	2020-05-07	Ablynx Nv	Improved immunoglobulin variable domains
WO2018111099A1 (en)	2016-12-12	2018-06-21	Stichting Vumc	Biomarkers and treatments for cerebral amyloid angiopathy (caa)
PL3461819T3 (en)	2017-09-29	2020-11-30	Probiodrug Ag	Inhibitors of glutaminyl cyclase

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7964192B1 (en) *	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
EP0954978B1 (en) *	1998-03-12	2011-11-30	VHsquared Limited	New products comprising inactivated yeasts or moulds provided with active antibodies
BR0009866A (en) *	1999-04-22	2002-01-08	Unilever Nv	Viral infection inhibition method, use of a monovalent antigen binding protein, food product, pharmaceutical or cosmetic composition, monovalent antigen binding protein, nucleotide sequence, expression vector, host cell, and selection and selection methods. identification of an antigen binding protein
DE1257584T1 (en) *	2000-02-24	2003-05-28	Lilly Co Eli	HUMANIZED ANTIBODIES THAT DETECT AMYLOID BETA PEPTID
GB0201611D0 (en) *	2002-01-24	2002-03-13	Grosveld Frank	Transgenic animal

2002
- 2002-11-06 FR FR0213866A patent/FR2846667B1/en not_active Expired - Fee Related
2003
- 2003-11-06 AU AU2003290158A patent/AU2003290158A1/en not_active Abandoned
- 2003-11-06 WO PCT/FR2003/003319 patent/WO2004044204A2/en not_active Ceased

Also Published As

Publication number	Publication date
FR2846667A1 (en)	2004-05-07
WO2004044204A2 (en)	2004-05-27
AU2003290158A1 (en)	2004-06-03
WO2004044204A3 (en)	2004-09-10
AU2003290158A8 (en)	2004-06-03

Publication	Publication Date	Title
FR2846667B1 (en)	2004-12-31	VARIABLE FRAGMENTS OF SINGLE-CHAIN CAMELIDE ANTIBODIES DIRECTED AGAINST BETA-AMYLOID PEPTIDE 1-42 AND THEIR APPLICATIONS FOR DIAGNOSIS AND TREATMENT OF NEUROAGREGATIVE DISEASES
AU2003299961A8 (en)	2005-10-27	Capsule and method for treating or diagnosing conditions or diseases of the intestinal tract
EP1187844A4 (en)	2003-09-03	CARBAMYL PHOSPHATE SYNTHETASE 1 POLYMORPHISM HUMAN; RELATED DIAGNOSTIC AND THERAPEUTIC METHODS
DE60224163D1 (en)	2008-01-31	COMBINATIONS OF EZETIMIBE AND ASPIRIN FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
EP1572116A4 (en)	2007-12-12	COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
IS5500A (en)	2000-05-17	Medicinal preparations for the stimulation and treatment of gastrointestinal disorders and related diseases
ATE252901T1 (en)	2003-11-15	MEDICINAL PRODUCTS FOR THE TREATMENT OF INFLAMMATORY HEART DISEASE
DE60226702D1 (en)	2008-07-03	LONG ACTING GLUCAGON-SIMILAR PEPTIDE-2 FOR THE TREATMENT OF GASTROINTESTINAL DISEASES AND DISORDERS
HUP9802212A2 (en)	1999-01-28	Recombinant anti-cd4 antibodies for human therapy
EP1360965A4 (en)	2009-07-29	METHODS OF TREATING DISEASES IN ASSOCIATION WITH DECREASING AOP-1 OR AOP-1 GENE EXPRESSION AND CON-US REMEDIES FOR SUCH DISEASES
GB9925804D0 (en)	1999-12-29	Biological materials and method useful in the diagnosis and treatment of diseases
EP1416964A4 (en)	2005-10-12	TREATMENT AND PREVENTION OF CANCER AND PRECANCEROUS DISEASES OF THE LIVER, LUNG AND ESOPHAGUS
EP1536829A4 (en)	2006-05-31	METHODS FOR THE PREPARATION OF STRESS OR ALPHA-2-MACROGLOBULIN PROTEIN COMPOSITIONS FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASES
NO976094D0 (en)	1997-12-29	New peptides derived from human heat shock protein 60 for the treatment of diabetes, method and kit
EP1377287A4 (en)	2007-11-14	PROANTHOCYANIDINES FOR THE TREATMENT OF AMYLOSES AND ALPHA-SYNUCLEIN-INDUCED DISEASES
FR2758143B1 (en)	1999-02-19	SPECIFIC INHIBITORS OF PANCREATIC LIPASE AND THEIR APPLICATIONS
DE50212280D1 (en)	2008-06-26	USE OF HMGB PROTEINS AND NUCLEIC ACIDS COORDINATING THEREOF
DZ3225A1 (en)	2001-05-10	METHOD AND COMPOSITIONS FOR THE TREATMENT OF LUNG DISEASES
WO2003055440A3 (en)	2004-08-26	Compositions and methods for the treatement of immune related diseases
AU2003278497A8 (en)	2004-01-06	Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases
AU2002364757A8 (en)	2003-06-10	Peptides for the production of preparations for the diagnosis and therapy of autoimmun diseases
AU3632899A (en)	1999-11-01	Method for the therapeutic and prophylactic treatment of dental diseases
DE60215060D1 (en)	2006-11-09	HERB PREPARATION FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND NEUROLOGICAL DISEASES
AU2002328212A1 (en)	2003-04-01	Diagnosis and treatment of early pre-type 1 diabetes glial fibrillary acidic protein
EP1408808A4 (en)	2005-01-05	METHODS OF DIAGNOSING AND TREATING CARDIAC DISEASES

Legal Events

Date	Code	Title	Description
2006-11-03	ST	Notification of lapse	Effective date: 20060731